ArteraAI vs DoMore Diagnostics (2026)
Both read routine H&E slides to estimate cancer risk and guide how much treatment to give, in different cancers and under different regulators. ArteraAI Prostate holds FDA De Novo authorization (DEN240068, July 2025) for 10 year risk from prostate biopsies, and the test is in the NCCN prostate cancer guidelines. DoMore's Histotype Px Colorectal places stage II and III colorectal cancer patients in risk groups to inform adjuvant chemotherapy, is CE-IVDD marked with no FDA clearance, and was validated in the QUASAR 2 trial cohort.
- Your patients have prostate cancer and you want an FDA authorized AI test.
- Guideline inclusion matters: the test is in the NCCN prostate cancer guidelines.
- You want a laboratory service, which the company states is fully reimbursed for Medicare patients.
- Your patients have stage II or III colorectal cancer and adjuvant chemotherapy is the decision.
- You work in Europe, where the test is CE marked.
- You want to run the test inside a platform you use: Sectra's Amplifier Marketplace, PathAI's AISight or Proscia's Concentriq Dx.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. ArteraAI and DoMore Diagnostics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | ArteraAI | DoMore Diagnostics |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | Not recorded | 2020 |
| Headquarters | Los Altos, California | Oslo, Norway |
| Website | artera.ai | domorediagnostics.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
ArteraAI
-
Clinical evidence
Artera announced five ASTRO 2026 presentations on its multimodal AI prostate cancer biomarker.
Source -
Regulatory / guideline
The ArteraAI Prostate Test was included in the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer, making it the first AI enabled risk stratification tool recommended in those guidelines.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
ArteraAI is the Los Altos, California company at artera.ai that builds multimodal AI cancer tests. It is unrelated to Artera of Santa Barbara (artera.io), which makes patient communication agents.
Source: AI Health Index, September 2026
Oslo based company whose Histotype Px Colorectal predicts recurrence and survival in stage II and III colorectal cancer from standard H and E stained slides, placing patients in risk groups to inform whether adjuvant chemotherapy should follow surgery. The product page states CE-IVDD marking; there is no FDA clearance.
Source: AI Health Index, September 2026
Questions buyers ask
How do ArteraAI and DoMore Diagnostics work with the EHR?
For ArteraAI, the authorized software takes images from FDA cleared scanners, which is scanner compatibility rather than record integration.
With DoMore Diagnostics, the products page says Histotype Px Colorectal is available on Sectra's Amplifier Marketplace, PathAI's AISight and Proscia's Concentriq Dx, and the partners page describes the Sectra and PathAI collaborations; PathAI's own algorithm menu lists the product. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are ArteraAI and DoMore Diagnostics priced and sold?
In ArteraAI's case, the home page says the test is fully reimbursed for Medicare patients and that many commercial health plans cover it, and it links a billing page and a No Surprises Act notice.
For DoMore Diagnostics, the company states that most stage II and III colorectal patients are cured by surgery alone and that adjuvant chemotherapy benefits few of them, so the value of Histotype Px is avoided chemotherapy and toxicity, and it presents the test as giving risk information soon after surgery. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do ArteraAI and DoMore Diagnostics handle patient data?
With ArteraAI, the Notice of Privacy Practices sets out who receives health information and why, requires patient authorization for marketing or any sale, and gates research use behind an institutional review or privacy board. The security page states AES-256 encryption at rest and encryption in transit on AWS.
In DoMore Diagnostics' case, the privacy policy covers personal data from website visits, email contact and job applications, with retention periods for those, and does not address slides or results from the product. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do ArteraAI and DoMore Diagnostics cover?
For ArteraAI, the authorized prostate software covers treatment naive core needle biopsies from men 55 and older without metastases who are candidates for curative treatment.
With DoMore Diagnostics, the company says it was developed on 4,500 patient samples and 90 million image tiles, with slides prepared at several sites and scanned at two sites on two different scanners, and it was validated in the QUASAR 2 trial cohort (The Lancet Oncology). Clinical validation studies are running with Gustave Roussy, Erasmus MC (up to 2,200 rectal cancer patients), IFOM Milan and Ohio State. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Artera's De Novo covers the software device, while the tests run in its own laboratory are laboratory developed tests it states are not FDA cleared. DoMore has no FDA clearance. Rewritten 28 Sep 2026 after both records were reviewed.